Thermo Fisher (TMO) Shares Up Since Jim Cramer Called the Firm “Unbelievable”

Company Overview - Thermo Fisher Scientific Inc. (NYSE:TMO) is a leading provider of diagnostic, laboratory products, and biopharmaceutical services globally, with significant exposure to the weight loss drug market [1] - The company manufactures Novo Nordisk's Wegovy weight loss drug by filling the injection pens [1] Stock Performance - Over the past year, Thermo Fisher's stock has decreased by 4.9%, but it has increased by 15% since Jim Cramer's positive remarks [1] - On July 23rd, the stock closed 9% higher following the release of its second-quarter earnings [1] - On October 1st, the stock again closed 9% higher after the announcement of a $2.5 billion bond offering for general corporate purposes [1] Financial Highlights - Thermo Fisher raised the lower end of its annual profit per share guidance to $22.22 from $21.76 [1] - The company reported a quarterly profit per share of $5.36, surpassing analyst estimates of $5.22 [1] Market Sentiment - Jim Cramer has expressed strong confidence in Thermo Fisher, describing it as a great company, but he cautioned against buying until there is an improvement in Chinese orders due to the stock's sensitivity to the Chinese market [1]